Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Study findings from University of Catanzaro Magna Graecia broaden understanding of HIV/AIDS
October 29th, 2008
According to recent research from Italy, "The recently released results of the Merck's Phase IIb ''test-of concept'' vaccine trials have shown no protection from HIV-1 infection in the vaccinated group compared with a control group vaccinated with placebo. The study was designed to test the Merck's MRKAd5 trivalent candidate vaccine." "The vaccine formulation was expected to stimulate a HIV-specific T cell immune response and to either prevent infection, or to reduce the levels of the viral load in vaccinated subjects. Upon the first evaluation of the interim data, the independent Data and Safety Monitoring Board ( DSMB) underscored no protection from HIV-1 infection in...
Source: Vaccine Weekly (2008-10-29)
|
